Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones

Dauw, Casey A.; Yi, Ya Sha; Bierlein, Maggie; Yan, Ping; Alruwaily, Abdulrahman F.; Ghani, Khurshid R.; Wolf, J. Stuart; Hollenbeck, Brent K.; Hollingsworth, John M.

doi:10.1016/j.urology.2016.03.030

Cited by 33 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Race/ethnicity was collected for White, Non-Hispanic Black, and Hispanic. Prescription drug use, which is associated with KS ( Dauw et al, 2016 ; Shafi et al, 2016 ), included statins, angiotensin-renin blockers, ACE inhibitors, beta blockers, calcium channel inhibitors, thiazide diuretics, loop diuretics, protease inhibitors, sulfonamides, and aminopenicillins. Other comorbidities included hypertension [diagnosis or an average of three systolic/diastolic blood pressure readings ≥130/85 mmHg], heart attack, stroke, congestive heart failure, coronary heart disease, angina pectoris, asthma, bladder cancer, gout, thyroid disease, and daily dietary laboratory data and behavioral data.…”

Section: Methodsmentioning

confidence: 99%

RETRACTED: Association between low-testosterone and kidney stones in US men: The national health and nutrition examination survey 2011–2012

Yücel

DeSantis

Smith

et al. 2018

Preventive Medicine Reports

View full text Add to dashboard Cite

The purpose of this study was to determine the association between low-testosterone (total testosterone ≤3 ng/mL) and prevalence of kidney stones (KS) in men 20 years and older, and whether this varies by comorbidities, and race/ethnicity, and age. This was a cross-sectional study with data from the National Health and Nutrition Examination Survey (NHANES) 2011–2012 cycle. We found that men with low-testosterone had 41% lower odds of KS as compared to men without low-testosterone after multivariable adjustment (OR: 0.59, 95% CI 0.40–0.86). When stratified by obesity, obese men with low-testosterone had 59% lower odds of KS. When stratified by HDL, men with HDL ≥ 40 mg/dL and with low-testosterone had 40% lower odds of KS. When stratified by diabetes, men without diabetes with low-testosterone had 39% lower odds of KS, but the association was not significant in diabetic men with low-testosterone and other comorbidities. There were significant differences when stratified by race/ethnicity. Finally, when stratified by age, only the subgroup of men ≥40–<60 years old with low-testosterone had 68% lower odds of KS (OR: 0.32, 95% CI: 0.16–0.67). The association between low-testosterone and KS was inversed. Similar associations were identified when stratified by obesity, diabetes, dyslipidemia, race/ethnicity and age.

show abstract

Section: Methodsmentioning

confidence: 99%

RETRACTED: Association between low-testosterone and kidney stones in US men: The national health and nutrition examination survey 2011–2012

Yücel

DeSantis

Smith

et al. 2018

Preventive Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Although multiple RCTs have shown a benefit of pharmacotherapy in preventing stone recurrence, compliance with prescribed drug regimens is often suboptimal. Using medical claims data, Dauw and colleagues [94] found that only 30.2% of kidney stone patients who were prescribed medications for stone prevention adhered to their drug regimen. Factors that were independently associated with lower likelihood of adherence included combination drug therapy, female gender, less comprehensive health insurance and residence in the South or Northeast of United States.…”

Section: Pharmacologic Managementmentioning

confidence: 99%

Medical therapy for nephrolithiasis: State of the art

Sorokin

Pearle

2018

Asian Journal of Urology

View full text Add to dashboard Cite

The prevalence of nephrolithiasis is increasing worldwide. Understanding and implementing medical therapies for kidney stone prevention are critical to prevent recurrences and decrease the economic burden of this condition. Dietary and pharmacologic therapies require understanding on the part of the patient and the prescribing practitioner in order to promote compliance. Insights into occupational exposures and antibiotic use may help uncover individual risk factors. Follow-up is essential to assess response to treatment and to modify treatment plans to maximize therapeutic benefit.

show abstract

“…However, the patients' compliance was poor. Dauw et al [30] found that when patients with kidney calculi were treated with a single prophylactic drug, the proportion of patients in the thiazide diuretic groups who followed the doctor's advice was only 42.5%. Even in the presence of cardiovascular diseases (e.g., hypertension), patients in the thiazide diuretic groups were equally less docile (42%) [31].…”

Section: Discussionmentioning

confidence: 99%

Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis

Gao

Liu

et al. 2020

J Transl Med

View full text Add to dashboard Cite

Background: Thiazide diuretics reduce the risk of recurrent kidney calculi in patients with kidney calculi or hypercalciuria. However, whether thiazide diuretics can definitely prevent recurrent kidney calculi remains unclear. We aimed to evaluate the effect and safety of thiazide diuretics on recurrent kidney calculi. Methods:The PubMed, Cochrane Library, and EMBASE databases were systematically searched using the keywords thiazide diuretics and kidney calculi to identify randomized controlled trials (RCTs). The primary outcome was the incidence of recurrent kidney calculi, and the secondary outcome was the 24-h urinary calcium level. The pooled risk ratio (RR), risk difference (RD), standardized mean difference (SMD), and 95% confidence interval (CI) were calculated. The evidence quality was graded using the GRADE criteria, and recommendations for recurrent kidney calculus prevention using thiazide diuretics were reassessed.Results: Eight RCTs involving 571 patients were included. The pooled RR for the incidence of kidney calculi in the thiazide diuretic groups was 0.44 (95% CI 0.33-0.58, P < 0.0001) compared to that in the placebo and untreated groups; the pooled RD was − 0.23 (95% CI − 0.30 to − 0.16, P < 0.0001). The pooled SMD for the 24-h urinary calcium level was − 18.59 (95% CI − 25.11 to − 12.08, P < 0.0001). The thiazide diuretic groups had a high incidence of adverse reactions and low tolerance. The evidence quality for decrease in kidney calculus incidence using thiazide diuretics was low, while that for the 24-h urinary calcium level decrease among those with recurrent kidney calculi was moderate, and that for the decrease in kidney calculus incidence using short-acting and long-acting thiazide diuretics was low. The overall strength of recommendation for prevention of recurrent renal calculi using thiazide diuretics was not recommended. The subgroup and sensitivity analysis findings were robust. Conclusions:Long-term use of thiazide diuretics reduces the incidence of recurrent renal calculi and 24-h urinary calcium level. However, the benefits are insufficient, and the evidence quality is low. Considering the adverse effects, poor patient compliance, and economic burden of long-term medication, their use in preventing recurrent kidney calculi is not recommended.

show abstract

Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones

Cited by 33 publications

References 22 publications

RETRACTED: Association between low-testosterone and kidney stones in US men: The national health and nutrition examination survey 2011–2012

RETRACTED: Association between low-testosterone and kidney stones in US men: The national health and nutrition examination survey 2011–2012

Medical therapy for nephrolithiasis: State of the art

Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis

Contact Info

Product

Resources

About